2023-2024 Fall Workshop Congregate Living Organizations September 12th, 2023

Hosted by Grey Bruce Public Health:

• Vaccine Preventable Diseases Program

PUBLIC

- Infectious Diseases Program
- Grey Bruce Public Health IPAC





Morning

- 8:30-9:00 am Registration
- 9:00-9:15 am Opening / Welcome / Land Acknowledgement
- 9:15-9:30 am Icebreaker
- 9:30-10:15 am Influenza and COVID-19 Vaccine Information / Other vaccinations

Break

- 10:15-1030 am
- 10:30-11:15 am Fall Respiratory Season
- 11:15-12:00 pm IPAC measures for outbreak management

Afternoon

- 1:00-2:00pm Self / Assisted Swabbing process
- 2:00-2:15 pm Ministry of Health Respiratory Season Readiness Exercise
- 2:15-2:30 pm Break
- 2:30-2:50 pm Start of Respiratory Season (phase 1)
- 2:50-3:10 pm Increased Respiratory Activity (phase 2)
- 3:10-3:45 pm Peak Respiratory Activity (phase 3)
- 3:45-4:05 pm Late Season Recovery (phase 4)
- 4:05-4:20 pm Closing Remarks

Today's Agenda

Welcome Dr. Rim Zayed Physician Consultant



Land Acknowledgement

Grey Bruce Public Health (GBPH) is situated on the traditional territory of the Nawash and Saugeen Nations, a place that has long served as a site of meeting and exchange amongst many First Nations including the Iroquois Confederacy, Huron/Wendat, Abenaki, and Anishinabek. GBPH recognizes and respects the Anishinabek as the traditional custodians of the lands and water. We are committed to supporting the Anishinabek and Haudenosaunee Peoples, among other First Nations, Inuit, Métis, and Indigenous Peoples globally.





Vaccine Preventable Diseases

- Influenza Vaccine
- COVID-19 Vaccine
- Adverse Reaction
- Vaccine Hesitancy
- Other Vaccines

Infectious Disease Team

- Outbreak Planning and Preparedness
- Reporting
- Line List
- Antiviral

IPAC

- IPAC
 - Outbreak preparedness
 - Outbreak control measures
 - Environmental services
 - Auditing and Surveillance
 - Personal Protective Equipment (PPE) burn rates and stock pilling
 - Continuing Education
 - Frequently asked questions

Morning Content



Vaccine Preventable Diseases

Presenter: Danielle McNabb, RPN Content: Danielle McNabb, RPN



2023-2024 Publicly Funded Influenza Vaccine Products

Quadrivalent (QIV)

Flulaval Tetra

Fluzone® Quadivalent

High-Dose Quadrivalent (HD-QIV)

Fluzone[®] High-Dose Quadrivalent

High-Dose Trivalent (HD-TIV)

Fluad®

2023-2024 Publicly Funded Influenza Vaccine Products

Product Name (Manufacturer)	Authorized ages for use	Format Multi- Dose Vial (MDV)	Available Single dose (PFS)	Most Common Allergens	Shelf Life <u>Multi-dose vial</u> (MDV) <u>Prefilled</u> syringes (PFS)	Route
Quadrivalent (QIV) Prod	ucts					
FluLaval [®] Tetra (GSK)	6 months and older	~		Egg proteinThimerosal	MDV: 28 Days	ІМ
Fluzone [®] Quadrivalent (Sanofi Pasteur)	6 months and older	~	✓	Egg ProteinThimerosal	MDV: 28 Days PFS: Not Applicable	IM
High-Dose Quadrivalent	(QIV) Products					
Eluzone [®] High-Dose Quadrivalent (Sanofi Pasteur)	65 years and older		✓	• Egg Protein	PFS: Not Applicable	IM
High-Dose Trivalent (TIV)) Product					
Eluad [°] (Seqirus)	65 years and older		✓	Egg proteinKanamycinNeomycin	PFS: Not Applicable	IM



2023-2024 Influenza Vaccine Strains

For the northern hemisphere's 2023-2024 season, the World Health Organization (WHO) has recommended the following strains be included:	Egg Based QIVs	Egg Based TIVs (<u>Fluad</u> ®)	Egg Based HD QIVs
A/Victoria/4897/2022 (H1N1) pdm09-like strain	\checkmark	✓	\checkmark
A/Darwin/9/2021 (H3N2)-like strain	✓	✓	\checkmark
B/Austria/1359417/2021-like strain	\checkmark	✓	\checkmark
B/Phuket/3073/2013-like strain	✓		\checkmark



COVID VACCINE

NACI continues to monitor the safety of concurrent administration of COVID-19 vaccines and other vaccines, including the seasonal influenza vaccine.

Beginning in the fall of 2023 for those previously vaccinated against COVID-19, NACI recommends a dose of the new formulation of COVID-19 vaccine for individuals in the authorized age group if it has been at least 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection (whichever is later).

Immunization is particularly important for those at increased risk of COVID-19 infection or severe disease, for example:

- Adults 65 years of age or older
- Residents of long-term care homes and other congregate living settings
- Individuals with <u>underlying medical conditions</u> that place them at higher risk of severe COVID-19
- Individuals who are pregnant
- Individuals in or from First Nations, Métis and Inuit communities*
- Members of racialized and other equity-deserving communities
- People who provide essential community services



Common side effects

Pain at injection site

Fatigue

Headache

Aching Muscles

Joint pain

Redness and swelling at the injection site

Fever

Feeling sick, diarrhea, vomiting, stomach pain



When to contact a medical professional

Allergic reaction

- Itchy rash of the hands and feet
- Swelling of the eyes and face
- Difficulty in breathing or swallowing
- Sudden drop on blood pressure and loss of consciousness



Adverse Events Following Immunizations (AEFIs) and Reporting

What is an AEFI?

Who should report an AEFI?

How do you report an AEFI when two vaccines are administered simultaneously?

How and where to report an AEFI?

Vaccine	Recommendation(s)
BCG	Consider use only in specified high-risk circumstances
Diphtheria Tetanus	All HCW should be immune Primary series if no previous immunization 1 Booster doses of Td vaccine every 10 years
Hepatitis B	If no evidence of immunity 2
Influenza	Annually
Measles	If no evidence of immunity (refer to text), regardless of age - 2 doses
Meningococcal	Not routinely for HCW Quadrivalent conjugate meningococcal vaccine for clinical laboratory workers who handle N. meningitidis specimens - 1 dose with a booster every 5 years if at ongoing risk
Mumps	If no evidence of immunity (refer to text), regardless of age - 2 doses
Pertussis	A single dose of Tdap vaccine if not previously received in adulthood.
Polio	Primary series if no previous immunization - 3 doses. Unvaccinated HCW at highest risk of exposure should be particularly targeted for primary immunization. A single lifetime booster dose for HCW at highest risk of exposure.
Rubella	If no evidence of immunity (refer to text) - 1 dose
Travel vaccines	For HCW planning to work abroad, consider hepatitis A, cholera, Japanese encephalitis, tick-borne encephalitis, typhoid, and yellow fever vaccines prior to departure Re-vaccination for some vaccines if ongoing risk.
Varicella	If no evidence of immunity (refer to text) - 2 doses
 Available indicated Post-imm 	as Td or Tdap or Tdap-IPV. Tdap is indicated if an adult pertussis dose is needed. Tdap-IPV is I if both pertussis and polio vaccinations are needed. nunization serologic testing within 1 to 6 months of completion of primary series.

Staff Immunization

Reference: Immunization of workers: Canadian Immunization Guide - Canada.ca



Reasons for incomplete immunization in adulthood

- Lack of recognition of the importance of adult immunization
- Lack of recommendations from health care providers
- Lack of health care provider's knowledge about adult immunization and recommended vaccines
- Misrepresentation and misunderstanding of the risks of vaccine and benefits of disease prevention in adults
- Lack of understanding of vaccine safety and efficacy
- Missed opportunities for vaccination in health care providers' offices, hospitals and nursing homes
- Lack of publicly funded vaccine and reimbursement to vaccine providers
- Lack of coordinated immunization programs for adults
- Lack of regulatory or legal requirements
- Fear of injections
- Lack of availability of up-to-date records and recording systems



Factors Contributing to Vaccine Hesitancy (4C's)

• Complacency

- Lack of perceived need or value for vaccine
- Lack of experience with vaccine-preventable diseases

• Convenience

- Lack of access (e.g. geographic barriers, cost barriers)
- Cost barriers

• Confidence

- Lack of trust in vaccine, provider, or the process
- Fear of being injected with a substance derived from disease-causing organisms
- Past adverse experiences
- Feeling intimidated
- Perceived risk/benefit
- Actual risk/benefit (technical concerns over probability of side effects)

• Culture

- Religious beliefs
- Social context and media personalities
- Distrust of the medical system or pharmaceutical industry
- Distrust in government



	High commitment to beliefs	Low commitment to beliefs
Low information needs	Believers: Follows vaccine schedules	Relaxed: May have some questions, but committed to vaccination
High information needs	Conscientious objectors: Reject vaccination and will not be swayed; close discussion skillfully	Cautious: Spend time describing benefits of vaccination

Information Health care providers should provide about immunization



Vaccine Hesitancy continued





Vaccine Hesitancy & Strategies

Vaccine position	Counselling strategy
Vaccine acceptors	 Encourage / promote resiliency Explain common side effects and rare adverse events Use verbal and numeric descriptions of vaccine and disease risks
Vaccine hesitant	 Build rapport, accept questions and concerns Establish honest dialogue, provide risk and benefit information about vaccines and diseases Use decision aids and other quality information tools Book another appointment to re-visit discussion, if needed
Vaccine refusers	 Avoid debating back and forth about vaccination Aim to keep discussion brief, but leaving door open to further discussion Inform about risks of non-vaccination Offer attendance at a special clinic





Vaccine Hesitancy & Strategies



Why do we vaccinate?

The most effective way to prevent influenza and its complications

Can help prevent the spread of influenza from person-toperson

Influenza can lead to severe disease, complications, or both, including hospitalization and death.

Influenza is the most common vaccine preventable disease leading to hospitalization and death in adults

Vaccinating helps manage health care system capacity during influenza season



Other vaccine recommendations

Herpes Zoster (Shingles)

Publicly funded for those between the ages of 65 & 70

2nd dose needs to be administered before the 71st birthday

Pneumovax 23 (Pneu-P-23)

Publicly Funded for those 65 years of age and older

Adacel (Tdap)

Publicly funded for 1 dose as an adult

Arexvy, an RSV vaccine has been approved for use in Canada

Questions?





Infectious Diseases & Outbreak Reporting

Presenter: Tammy Aitken, BScN, Kelly McPhatter RN BScN, Teresa Arsenault, RPN, Monica Blair RPN Content: Monica Blair, RPN , Colleen Carney, RN BScN, Teresa Arsenault, RPN





Objectives

Re-introduce the Infectious Disease Team

Outbreak Preparation

Outbreak Management





Infectious Disease Team

ID Team is divided into 4 zones that cover the LTCHs, RHs and other Congregate Living Homes in Grey Bruce

Each zone is assigned Public Health staff that support their area homes

Contacting the Infectious Disease Team

Non-urgent matters

Contact the ID team at 519-376-9420 x6

Fax Number: 519-376-4152

Urgent Matters and Outbreak Reporting

Helpline	After Hours
Monday-Friday	7 days/week
8:30-4:30	4:30pm-8:30am
Extension 6	519-376-5420



Outbreak Preparation

Materials

Personal Protective Equipment (PPE)

• Droplet/Contact/Airborne

Test Kits! – check expiry dates!

Isolation Carts and Signage

Alcohol Based Hand Rub – check expiry dates!

Disinfectants

Keep a good supply of other diagnostic kits on hand for routine testing purposes!



Ontario 🕅

Outbreak Preparation

Documents/Resources

Policies & Procedures

Guidance Documents

Staff Training & Education

Checklists

Reference Materials

PHO IPAC Review

Units: Long-Term Care Homes, **Retirement Homes, and Other** Congregate Living Settings OUTBREAK NUMBER: 2233 - 20 ____ Date declared: Type: Respiratory Gastroenteritis Status: Suspect Confirmed Version 11 - June 26, 2023 Date identified: Case Definition: **Highlight of Changes: Reporting to Public Health** Added that the requirements in the guidance should be followed during Contact Grey Bruce Public Health when any of the follo periods of non-high-risk COVID-19 transmission. Respiratory/Influenza - Suspect or Confirmed Infection Outbreak Definitions: Suspect respiratory infection outbreak dentitions: Two cases of acute respiratory tract illness (ARI) occurring within 48 hours with any common epidemiological I · Added a recommendation for staff to consider masking for source control (e.e. unit floor): OR during prolonged direct (<2metres for >15 minutes) care indoors and One laboratory confirmed case of influenza outdoors med respiratory infection outbreak definitions: Two cases of acute respiratory tract illness (ARI) within 48 hours with any common epidemiological link (e.g., unit, · Visitors and caregivers are recommended, but no longer required, to wear a floor), at least one of which must be lab confirmed; OR mask indoors when visiting settings that are not in outbreak. Three cases of acute respiratory illness (laboratory confirmation not necessary) occurring within 48 hours with an Added clarity on visitor restrictions after visitor tests positive or is common epidemiological link (e.g., unit, floor) symptomatic COVID-19 - Suspect or Confirmed Outbreak Definitions: Added information on staff return to work staff tests positive or is Suspect COVID-19 outbreak definition One positive PCR OR rapid molecular (ID NOW) test OR rapid antigen test in a resident who has reasonably acquine test in a reasonably acquine test in a reaso symptomatic their infection in the home · Revised LTCH/RH resident isolation requirements (i.e., residents able to Confirmed COVID-19 outbreak definition: Two or more residents with a common epi link (e.g.,2, same unit, floor, etc.), each with a pos rapid antigen test, within a 7-day period Managing COVID-19 Outbreaks in essing residents for COVID Public Health Ontario Gastroenteritis – Suspect or Confirmed Infection Outbreak Definitions: Congregate Living Settings (CLS) To be defined as a case of infectious gastroenteritis, at least one of the following must be met Two or more episodes of diarrhea (i.e., loose/watery bowel movements) within a 24-hour pe 2- Edition: March 2023 Two or more episodes of vomiting within a 24-hour period; OR One or more episodes of diarrhea AND one or more episodes of vo When to Use This Checklist Laboratory confirmation of a known gastrointestinal pathogen and at least one symptom com This checklist is intended to be used when a CLS (e.g., shelters, group homes, supportive housing) has a suspect or confirmed outbreak of COVID-19. If the CLS has multiple pathogens circulating during the intertinal infection Note: Symptoms must not be attributed to another cause (e.g., medication side effects, laxatives, outbreak, this checklist should be used to manage COVID-19 only. Suspected gastroenteritis outbreak definition nation reparding influenza, refer to Public Health Ontario's Influenza,1 The CLS should refer to the If an outbreak is suspected, notify the Health Unit to support with the investigation and n dinistry of Health COVID-19 Guidance for the most up to date definition of a COVID-19 out onfirmed gastroenteritis outbreak definitions: This checklist is not intended for use in long-term care homes and retirement homes (a specific checklist Two or more cases meeting the case definition with a common epidemiological link (e.g., spec This creations and small before user any structure and an any structure and the stru caregiver) with initial onset within a 48-hour period. Note: Outbreaks can exist outside the outbreak definition parameters. Public Health is available for con experiencing increased illness above your normal thresholds This checklist should be used in addition to - but does not replace - the advice, guide nendations, directives or other direction of provincial Ministries and local public health units (PHUs Fax Initial Line listing of Residents and Staff to 519-376-4152 See the Ministry of Health's COVID-19 Guidance: Long-Term Care Homes, Retirement Homes, and Others Obtain case definition from Public Health Get un winning yo reasing EU/ULD is section Corporation Transfer, Martine Transfer, Martine Transfer, Additional resources are also available on PHO's COVID-19 Resources for Congregate Living Settings webpage," including a COVID-19 Resources and Investigation of Research and Obtain Outbreak Number from Public Health Contents 1 - Outbreak Management - Initial Step 2 - Clients in Outbreak Area 3 - Staff and Visitors 4 - Testing 5 - Transportation 6 - Activities and Meals 7 - Infection Prevention and Control (IPAC) 8 - Ventilation 9 - Screening and Monitoring 10 - Communications 11 - Declaring an Outbreak Over . 12 - Appendix A: Outbreak Line List

13 - References

Ministry of Health

COVID-19 Guidance for Public Health



Symptoms and Surveillance

What are you looking for?

Fever	Chills
Cough	Shortness of Breath
Sore throat	Runny nose
Nasal congestion	Olfactory Disorders
Nausea/Vomiting	Diarrhea
Abdominal Pain	Headache

Look at what else is occurring...





Identification and Testing

"Outbreak Assessment"

At least 1 resident with new symptoms compatible with acute respiratory infection (ARI)

Next Steps...

Isolate or exclude symptomatic resident

Obtain specimen for testing – from symptomatic resident

Line list (fax to 519-376-4152)

Testing Reminders

Ensure staff are trained in proper specimen collection

Check expiration date of kits



COVID-19 Outbreak Case Definition

Declaring an outbreak is usually based on resident illness activity and <u>not</u> staff. If unsure, call ID Helpline.

Outbreaks can exist outside of outbreak definition parameters. Please report any suspected or confirmed respiratory illness to Public Health.



Reporting and Declaring an Outbreak

Fill out a line list and ensure to complete all fields listed. Separate line lists are to be used for residents and staff.

Fax line list to 519-376-4152

AND

Call to report outbreak to ID Helpline at 519-376-9420 ext. 6

Implement outbreak control measures

Outbreak - Respiratory Line List - Resident (SVC-ID) Outbreak Number 2233-20 ____

Facility: _____ Telephone:

Facility Contact Person:

Fax Daily to Grey Bruce Health Unit: 519-376-4152

Unit: Date declared:

Total Residents in Unit:

Total Residents in Facility: Alternate Contact Person:

Pathogen: _____ Date identified: _____

Case Informatio	n				<i>a</i> 3					Symp	otom	3			ar					Diag	nosis		. V.	Prophy	ylaxis / tment		Но	sp.	Outo	omes
Name	Room #	Received Flu Vaccine (Y/N)	# COVID-19 Vaccine doses	Date of Onset	Abnormal Temperature / fever	Chills	Cough (dry or productive)	Shortness of Breath	Sore throat / Hoarseness / Difficulty Swallowing	Runny Nose / sneezing / Nasal Congestion	Olfactory or Taste Disorder (new)	Nausea / Vomiting	Diarrhea	Myalgia (muscle pain)	Fatigue / Malaise	Headache	*Other	None	Pneumonia (C-Clinical / R-Radiography)	Rapid Antigen Test (date, + / -)	NP Swab Collected (date)	COVID Results (+ / -)	Flu Antiviral Prophylaxis (date)	Flu Antiviral Treatment (date)	COVID Antiviral Treatment (date)	Antibiotic	Date Admitted	Date Discharged	Deceased (date)	Date Out of Isolation
					5	2 2	2		2																					
																	24													
																8	8		8											
2022				101 1	17 ⁶ St	E.O	wen So	ound	ONN	4K 0A5	WW	W.D	ubl	iche	alth	gre	vbru	ice.	on ca	519-3	76-9420	ß			Pac	le		of		2

09/



Controlling an Outbreak

Communication – internal and external

Control Measures

Environmental Cleaning

Case Management

Specimen Collection and Testing

Enhanced Surveillance

Antivirals

These will be happening at the same time!

It is important to have your own internal

outbreak management plan

Outbreak Management

Communications

Internal – Staff

Implement outbreak management plan

Notify all staff of their roles and responsibilities

Ensure <u>all</u> staff are aware of control measures, precautions, reporting illness, surveillance, etc.

Internal – Residents

Inform residents of outbreak and what to expect

External – Visitors, Partners, Family

Post outbreak signage on all entrance doors

Educate visitors on outbreak control measures

Communicate outbreak status to relevant partners

Send updated line lists daily to Public Health. Call after hours for any urgent reporting

Notify Ministry of Labour re: staff illness if required


Control Measures

A sliding scale – dependent on many factors!



Suspected Outbreak – not a bad thing!

- "Business as usual" with a few exceptions
- Enhanced surveillance for new cases
- Enhanced cleaning/disinfection
- Ensure all materials (isolation carts, PPE, etc.) are available if a confirmed outbreak develops

Staff

- Routine practices
- Additional Precautions contact/droplet/airborne
- Point of Care Risk Assessment (PCRA)
- Cohort well staff
- Exclude ill staff

Residents

- Promote hand hygiene
- Isolate ill residents
- Postpone events and activities
- Reschedule non-urgent appointments
- Re-assess admissions and transfers
- Delay non-essential visiting

Environmental Services

- Verify disinfectant is appropriate
- Increase frequency of cleaning and disinfection
- Dedicated cleaning cart for outbreak unit/floor or for each unit. If not able, cleaning cart is to be cleaned and disinfected between units/floors

Adapt and change outbreak measures as needed!

Control Measures – CONFIRMED COVID-19

Case Management

Symptomatic Residents

Isolate with appropriate precautions

Obtain specimen for testing

Symptomatic Staff

Report symptoms

Testing is per home policy and procedure



Case Management - Isolation and Return to Work

	COVID-19	When COVID-19 Has Been Ruled Out
Residents	 5 days after symptom onset or positive test, and until no fever and symptoms are improving x24h (48h if gastrointestinal symptoms) Until at least day 10 from symptom onset or positive test, continue to wear a well-fitted mask 	Respiratory Symptoms: 5 days after onset of symptoms or when symptoms resolve (whichever is sooner) Gastrointestinal Symptoms: 48h after symptoms resolve
Staff or Volunteers	Follow internal return to work (RTW policy)	Respiratory Symptoms: 5 days after onset of symptoms or when symptoms resolve (whichever is sooner) ** Gastrointestinal Symptoms: 48h after symptoms resolve

******This is direction for outbreak scenarios. Non-outbreak RTW is based on home policy.



Specimen Collection and Testing

Collect specimens from 2-3 residents with acute symptoms

Fill out requisition entirely AND double check it matches the specimen label

Store it in the fridge or on ice

Submit asap or within 72 hours





Health public Ontario Ontario	spiratory	For laboratory use only Date received (yyyyimmidd): ALL Sections of this form must be completed at every visit		
/irus Test Requis	ition			
1 - Submitter Lab Number	(if applicable):	2 - Patient Information	2 - Patient Information	
Orderlage Officialize transfer di	(in approved).	Health Card No.:	Medical Record No.:	
Sumame First Name			6	
OHID/CPSO/Drof License No:		Last Name:		
Name of states				
facility/health unit:		Date of Birth		
Address:	Postal code:	(yyyyimmidd):	Sex OM OF	
		Address:		
Phone:	Fax:			
cc Hospital Lab (for entry	into LIS)	Postal Code:	Patient Phone No.:	
Hospital Name:		Investigation or Outbreak No.		
Address (if different		3 - Travel History	3 - Travel History	
Bostal Code:		Travel to		
Postal Code.		Date of Travel	Date of Return	
Phone.	Pac	(yyyyimmidd):	(yyyy/mm/dd):	
cc Other Authorized Healt	th Care Provider:	4 - Exposure History		
OHIP/CPSO/Prof. License No.: Name of clinic/ facility/health unit:		Exposure details: Date of symptom onset of contact	ct (yyyy/mm/dd):	
Address:	Postal code:	5 - Test(s) Requested		
Phone:	Fax	COVID-19 Resp Virus Virus	piratory ses OCVID-19 Virus AND Respirator Viruses	
- Specimen Type (check all	that apply)	7 - Patient Setting / Type	0	
Pecimen Collection Date (yy) NPS The Deep or Mid-turbinate Nasal Swab Oral (Buccal) Oral (Buccal) Colle Deep Nasal Oral (Buccal) Oral (Buccal)	yhmridd): (required) at Swab Salva (Swith & Gargle) oat + Nasal Salva (Neat) Anterior Nasal (Nose er (Specify): Statue	Assessment Fan Centre Fan Only if applicable, indicate the gro ER - to be hospitalized Healthcare worker Inpatient (Hospitalized)	may	
Received all required doses >14 days ago	Unimmunized / partial) series / s14 days after Unknown final dose	Remote Community	Confirmation (for use ONLY by a COVID testing lab). Enter your result (NEG / POS / or IND):	
		Unnoused / Sherief		
Asymptomatic Fev	Pregnant	Other (Specify):		
Symptomatic Pne	eumonia Other (Specify):	CONFIDENTIAL WHEN COMPL	LETED	
Date of symptom Cough onset (yyyy/mm/dd): Sore Throat		The personal health information is collected under the authority of the Personal Health Information Protection Act, a 36(1)(c)(iii) for the purpose of clinical isobratory testing, if you have questions about the collection of this personal health information piezae contact the PHO laboratory Manager of Customer Service at 46-523-6366 or to the 1-137-604-547.		

Fill out as much as possible! Don't forget...

Ordering Provider

GBPH will be the ordering provider when

- A resident or staff is symptomatic
- A resident, staff or visitor is a high-risk contact of COVID-19
- An OB has been declared
- Public health advises testing

Patient Information

- ALWAYS include HCN
- Outbreak Number

Tests Requested

COVID-19 Virus AND Respiratory Viruses

Patient Setting

• Institutional

Clinical Information

 Asymptomatic vs Symptomatic – lab will not process multiplex panel or FLUVID unless the resident is symptomatic



Laboratory Testing

Respiratory

- Multiplex respiratory virus panel (MRVP) Influenza A, influenza B, respiratory syncytial virus (RSV), parainfluenza, adenovirus, enterovirus, seasonal human coronavirus, rhinovirus and human metapneumovirus. White lid container. Up to 4 specimens per outbreak. Must be symptomatic
- FLUVID Influenza A, Influenza B, RSV, and SARS-CoV-2 (COVID-19) unlimited. Lab will test for FLUVID after the 4 specimens for MRVP has been used. Must be symptomatic
- SARS-CoV-2 (COVID-19)





Co-infection - Now what?

Respiratory Virus AND COVID-19 detected

Continue with COVID-19 control measures

First four symptomatic residents will be tested for MRVP and COVID-19. All other symptomatic residents will be tested for FLUVID

COVID-19 treatment is the decision of the health care provider

Influenza AND COVID-19 are detected

Influenza antiviral prophylaxis may be initiated for all asymptomatic residents and residents who are COVID+/influenza negative until the influenza outbreak is declared over (as per most responsible physician)

Influenza antiviral treatment may be initiated for influenza positive residents per guidelines (as per most responsible physician)

For COVID-19 positive residents, both Tamiflu and Paxlovid can be given at the same time; however, given potential drugdrug interactions, the decision to initiate treatment is at the discretion of the treating health care provider



Access to COVID-19 antiviral treatment (Paxlovid):

Information for primary care providers and other health care providers caring for patients in the community

Background and scope

Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral medication that can reduce the risk of hospitalization or death in people at higher risk of serious illness due to COVID-19

Paxlovid must be administered within five days of symptom onset to be effective.

This document outlines how primary care providers and other health care providers can access Paxlovid for patients in the community.

This document focuses on access to Paxlovid. Remdesivir, an intravenous antiviral medication administered as a three-day course, may also be available for people at higher risk of serious illness due to COVID-19 who cannot take Paxlovid or as an alternative to Paxlovid, based on clinical assessment. Remdesivir is available at eight treatment clinics across the province and is also available to hospitals via their inpatient supply. Providers should contact their Ontario Health regional contact to learn more about local pathways to access remdesivir for outpatients.

Who is eligible for Paxlovid

All patients who are at higher risk of severe outcomes based on clinical assessment, have tested positive (PCR, rapid molecular, or rapid antigen test [including self-administered]), are mildly ill, present within five days of symptom onset, and do not have contraindications are eligible for Paxlovid based on clinician judgement.

Public messaging will encourage anyone who may be at higher risk of severe outcomes (based on the criteria listed below) to seek testing and an assessment (see Ministry of Health website and screener tool). Clinicians will need to assess these patients and determine whether treatment with Paxlovid is appropriate.

The criteria below outline who may be at higher risk of severe outcomes, based on the product monograph and Health Canada authorization for Paxlovid. The risk of severe outcomes will vary among individuals who meet these criteria. The Ontario COVID-19 Science Advisory Table's guidelines outline who would most benefit from Paxlovid based on a 5% or higher risk of hospitalization. Providers should use their clinical judgment in determining whether treatment with Paxlovid is appropriate.

Patients may be at higher risk of severe outcomes if they are:

- immunocompromised (have an immune) system that is weakened by a health condition or medications):
- 70 years of age and older
- 60 year of age and older with less than three vaccine doses: or

18 years of age or older with less than three vaccine doses and at least one risk condition.

Risk conditions include:

- diabetes intellectual or developmental
- obesity disability
- heart disease cerebral palsy hypertension
- sickle cell disease congestive heart failure
- moderate or severe chronic respiratory liver disease

pregnancy

- disease (including cystic fibrosis)
- moderate or severe kidney disease

Drug-drug interactions leading to potentially serious and/or life-threatening reactions are possible due to the effects of ritonavir on the hepatic metabolism of certain drugs. Contraindications and interactions must be carefully considered before Paxlovid is prescribed.



COVID-19 Antiviral Treatment

- •Resident antiviral treatment for COVID-19 is to be assessed by a health care provider to determine if they meet criteria.
- •Clients are encouraged to speak with their primary care provider regarding a treatment plan in case they get sick.
- Ontario Health has provided a document on how to access COVID-19 antiviral treatment.
- •At this time, COVID-19 antivirals are only for treatment.

Last updated: April 11, 2022



Influenza Antivirals

• Resident antiviral medication in an influenza outbreak

- Well residents may be given antiviral prophylaxis until the outbreak is declared over
- Ill residents may be given treatment dosing as soon as possible, within 48 hours of symptom onset
- At the discretion of their health care provider

• Staff antiviral medication

- Ill staff should remain off work until the period of communicability (5 days from onset for influenza) has passed. This includes staff on antiviral medication.
- Well staff who are unimmunized should immediately be offered the flu vaccine and may consult their health care provider regarding the use of antiviral prophylaxis for two weeks after vaccination <u>OR</u> if not being immunized, may take antiviral prophylaxis until the outbreak is declared over at the discretion of their Health care Provider (can return to work after first dose) <u>OR</u> may be excluded from work until the outbreak is over (as per internal policies)

*Unvaccinated staff are recommended to obtain an antiviral prescription from their primary care provider in advance of the flu season. This will allow for rapid initiation of antivirals and limit staff shortages.



Declaring the Outbreak Over

7 days from the last outbreak related case

If there is a new resident case identified with no risk to the home because that resident has been isolating (e.g., roommate), the case will be counted as part of the outbreak but would not extend the duration of the outbreak

 Outbreaks are declared over in consultation with Public Health, but is dependent on several criteria

Questions?





INFECTION PREVENTION AND CONTROL

Presenter: Adel Coulter, RPN,CIC and Krista Witzke, RN BScN Content: Krista Witzke, RN BScN and Adel Coulter



Hierarchy of Controls



Reference <u>Hierarchy of Controls</u> | NIOSH | CDC





Fall Planning & Preparedness

> Each organization should identify:

- Outbreak lead and back up
- Members of the outbreak management team (OMT)
- IPAC lead and back up
- How Grey Bruce Public Health IPAC can be utilized to provide IPAC support
- Ensure the following are up-to-date:
 - Contact lists for staff, caregivers, families, regular non-essential visitors
 - Line lists

≻Supplies:

- Adequate stock of all supplies (PPE, hand hygiene, environmental cleaning, diagnostic, etc.), secure your vendors
- Signage for additional precautions is printed and easy to access
- Ensure you have a supply of Testing kits (nasopharyngeal, gastroenteritis kits, RATs, etc.)



Outbreak Preparedness

Have your Shopping list for IPAC Preparedness ready:

- ✓ Specimen collection kits prepared, check expiry dates
- ✓ Have the PPE storage carts ready to go, aim to have 1 per resident
- Alcohol based hand rub (ABHR), check expiry dates and placement of ABHR wall units and pump bottles throughout the home
- ✓ Outbreak signage is printed and easy to access
- ✓ Cleaning products
- Outbreak management policy and procedure ready and easily accessible for all staff
- ✓ Ensure appropriate staffing levels to maintain proper environmental cleaning



PPE Storage Rooms







Control Measures for Staff

Routine Practices

Additional Precautions

Cohort staff to well and ill residents

Exclude ill staff

Enhanced environmental cleaning



Control Measures for Residents

Promote hand hygiene

Isolate ill residents in their rooms

Postpone events and activities facility wide or outbreak unit

Reschedule non-urgent appointments

Discuss admissions and transfers with Public Health

Limit certain games/activities which cannot be easily cleaned & disinfected







Control Measures for Visitors

Inform visitors and family of outbreaks	Encourage proper hand hygiene	
Educate visitors on proper PPE use	Discourage general visitors depending on the outbreak	
Promote flu and		

covid immunizations to family and frequent visitors

1	BEFORE initial patient/patient environment contact	WHEN?	Clean your hands when entering: • before touching patient or • before touching any object or furniture in the patient's environment
		WHY?	To protect the patient/patient environment from harmful germs carried on your hands
2	BEFORE aseptic procedures	WHEN?	Clean your hands immediately before any aseptic procedure
		WHY?	To protect the patient against harmful germs, including the patient's own germs, entering his or her body
3	AFTER body fluid exposure risk	WHEN?	Clean your hands immediately after an exposure risk to body fluids (and after glove removal)
		WHY?	To protect yourself and the health care environment from harmful patient germs
4	AFTER patient / patient environment contact	WHEN?	Clean your hands when leaving: • after touching patient or • after touching any object or furniture in the patient's environment
		WHY?	To protect yourself and the health care environment from harmful patient germs
iapted f	from WHO poster "Your 5 mom	ents for Hand Hy	giene," 2006.

For more information, please contact handhygiene@oahpp.ca or visit publichealthontario.ca/JCYH





R	OUTINE PRACTICES to be used with <u>ALL PATIENTS</u>
Y GDB3	Hand Hygiene Hand hygiene is performed using alcohol-based hand rub or soap and water: ✓ Before and after each client/patient/resident contact ✓ Before performing invasive procedures ✓ Before preparing, handling, serving or eating food ✓ After care involving body fluids and before moving to another activity ✓ Before putting on and after taking off gloves and PPE ✓ After personal body functions (e.g., blowing one's nose) ✓ Whenever hands come into contact with secretions, excretions, blood and body fluids
R	 Mask and Eye Protection or Face Shield [based on risk assessment] ✓ Protect eyes, nose and mouth during procedures and care activities likely to generate splashes or sprays of blood, body fluids, secretions or excretions. ✓ Wear within two metres of a coughing client/patient/resident.
2	Gown [based on risk assessment] ✓ Wear a long-sleeved gown if contamination of skin or clothing is anticipated.
CAR I	Gloves [based on risk assessment] ✓ Wear gloves when there is a risk of hand contact with blood, body fluids, secretions, excretions, non-intact skin, mucous membranes or contaminated surfaces or objects. ✓ Wearing gloves is NOT a substitute for hand hygiene. ✓ Remove immediately after use and perform hand hygiene after removing gloves.
	 Environment and Equipment ✓ All equipment that is being used by more than one client/patient/resident must be cleaned between clients/patients/residents. ✓ All high-touch surfaces in the client/patient/resident's room must be cleaned daily.
S	Linen and Waste ✓ Handle soiled linen and waste carefully to prevent personal contamination and transfer to other clients/patients/residents.
And a second	Sharps Injury Prevention ✓ NEVER RECAP USED NEEDLES. ✓ Place sharps in sharps containers. ✓ Prevent injuries from needles, scalpels and other sharp devices. ✓ Where possible, use safety-engineered medical devices.
	Patient Placement/Accommodation ✓ Use a single room for a client/patient/resident who contaminates the environment. ✓ Perform hand hygiene on leaving the room.





Hand Hygiene as per Routine Practices Hand hygiene is performed: * Before and after each resident contact * Before performing invasive procedures * Before perparing, handling, serving or eating food * After care involving body fluids and before moving to another activity * Before putting on and after taking off gloves and other PPE * After personal body functions (e.g., blowing one's nose) * Whenever hands come into contact with secretions, blood and body fluids

DROPLET + CONTACT PRECAUTIONS – Non-acute Care Facilities

	 After contact with items in the resident's environment Whenever there is doubt about the necessity for doing so
	Resident Placement
	✓ Single room with own toileting facilities if resident hygiene is poor and if available, or maintain a spatial separation of at least 2 metres between the resident and others in the room, with privacy curtain drawn
	✓ Door may remain open
	✓ Perform hand hygiene on leaving the room
	Mask and Eye Protection or Face Shield
	✓ Wear within 2 metres of the resident
	\checkmark Remove and perform hand hygiene on leaving the room
	Gown and Gloves [based on risk assessment]
R	✓ Wear a long-sleeved gown for <u>direct care</u> * when skin or clothing may become contaminated
100	✓ Wear gloves for <u>direct care</u> *
W. 5.	✓ Wearing gloves is NOT a substitute for hand hygiene.
	\checkmark Remove gloves on leaving the room or bed space and perform hand hygiene
5	Environment and Equipment
Ø.	✓ Dedicate routine equipment to the resident if possible (e.g., stethoscope, thermometer)
d'	✓ Disinfect all equipment before it is used for another resident
Ð	\checkmark All high-touch surfaces in the patient's room must be cleaned at least daily

2



* <u>Direct Care</u>: Providing hands-on care, such as bathing, washing, turning the patient, changing clothing, continence care, dressing changes, care of open wounds/lesions or toileting. Feeding and pushing a wheelchair are not classified as direct care.



ADDITIONAL PRECAUTIONS

<u>bp-rap-healthcare-settings.pdf</u> (publichealthontario.ca)





Gastrointestinal Contact Precautions

gloves & gown





Respiratory Droplet & Contact Precautions

gloves, gown mask & goggles



Developed by South West IPAC Hub



Staff Education | IPAC Huddles

Source of training may come from PHO, IPAC Canada, Grey Bruce Public Health IPAC, or your organizations corporate training

- IPAC Education occurs on a regular, ongoing and on-the spot basis:
 - Point-of-Care and Personal Risk Assessment
 - PPE Use (appropriate use, donning and doffing)
 - Hand Hygiene
 - For themselves as well as their role in promoting hand hygiene for residents
 - Environmental Cleaning (contact times, concentration, frequency, etc.)
 - Everyone in the home has a role to play in environmental cleaning, not just the Environmental Services team
 - Outbreak response, reporting and isolation protocols
 - It is important to build capacity within your homes so that all staff understand the processes of surveillance, reporting and isolation procedures



Importance of Environmental Services

"In the Healthcare setting, the role of the environmental cleaning is important because it reduces the number and amount of infectious agents that may be present and may also eliminate routes of transfer of microorganisms from one person/object to another, thereby reducing the risk of infection"



Cleaning and disinfecting products	Safe work practices	Contact times	High touch surfaces
Cleaning practices	Workflow	No "double- dipping"	Waste/Laundry

Reference: Public Health Ontario (PHO), Key Elements of Environmental Cleaning in Healthcare Settings Fact Sheet, July 16, 2021 Welcome | Public Health Ontario

Environmental Cleaning | Considerations

Deciding what products to use



Reference <u>PIDAC: Best Practices for Environmental Cleaning for Prevention and Control of</u> Infections | January 2018 (publichealthontario.ca)





Regular and ongoing assessments

- Assess health and safety measures
- IPAC checklists and processes
- Auditing (hand hygiene, PPE, cleaning, isolation practices, etc.)
- Regular capacity planning
- Ventilation

Preparation and review

- Review of isolation protocols, print signage
- PPE procurement (secure vendors, contact information easily available)
- o Plan to cohort staff and residents (mock exercises)



Reference: Hierarchy of Controls | NIOSH | CDC

Infection Prevention and Control Organizational Risk Assessment



PPE & Burn Rates

https://www.cdc.gov/niosh/topics/pandemic/ppe.html



Frequently Asked Questions

FAQ (publichealthgreybruce.on.ca)









Community of Practice / Networking



Developing IPAC Programs, Policies and Procedures



Supporting Assessments and Audits of IPAC Programs and or Practices



Recommendations to Strengthen IPAC Programs and Practices



Working with Public Health Partners



Coaching and Mentoring



Supporting Settings to Implement IPAC

How can Grey Bruce Public Health IPAC assist your home?

Questions?


Key Resources

- Ø Grey Bruce IPAC (publichealthgreybruce.on.ca)
- Ø Grey Bruce Public Health (publichealthgreybruce.on.ca)
- COVID-19: Infection Prevention and Control Checklist for Long-Term Care and Retirement Homes (publichealthontario.ca)
- COVID-19 Preparedness and Prevention in Congregate Living Settings (publichealthontario.ca)
- Ø Health Care Huddles: IPAC Checkpoints (publichealthontario.ca)
- Ø Online Learning | Public Health Ontario
- Ø Personal Protective Equipment (PPE) Auditing | Public Health Ontario
- Ø Just Clean Your Hands Long-term Care | Public Health Ontario
- PPE Burn Rate Calculator https://www.cdc.gov/niosh/topics/pandemic/ppe.html
- Ø Best Practices in IPAC | Public Health Ontario



Contacts

Vaccine Preventable Diseases Team

Phone: 519-376-9420, press 2

Email: <u>immunization@publichealthgreybruce.on.ca</u>

Infectious Diseases Team

Phone: 519-376-9420, press 6

Email: infectiousdiseases@publichealthgreybruce.on.ca

Grey Bruce Public Health IPAC

Phone: 519-376-9420, Krista ext. 1373, Adel ext. 1466

Email: ipachub@publichealthgreybruce.on.ca





Thank you for all that you do for your residents, colleagues, families and community!





Public Health Ontario IPAC Central West and West

 Novice ICP – CoP 1-2pm (Broadcasted)

Fall/ Winter 2023/24 Respiratory Seasons Readiness Exercise

- Phase 1 Start of Respiratory Season
- Phase 2 Increased Respiratory Activity
- Phase 3 Peak Respiratory Activity
- Phase 4 Late Season Recovery
- Hotwash

Afternoon Content